Key information

🔎 Fund Overview

CARGO Therapeutics, Inc. is a biotechnology company focused on the development of best-in-class and potentially curative cell therapies for cancer patients. It has a focused pipeline that includes its CRG-023 product candidate, a CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a range of B-cell malignancies with the goal of providing more patients with a durable complete response. Its latest program advancement, an allogeneic platform, is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. The universal allogeneic-enabling vector is intended to be paired with any CAR vector to create an allogeneic CAR T-cell therapy, with the potential to maintain the efficacy, durability, and safety of autologous cell therapy while broadening availability to more people with cancer.